» Articles » PMID: 36959801

Plasma-only Circulating Tumor DNA Analysis Detects Minimal Residual Disease and Predicts Early Relapse in Hepatocellular Carcinoma Patients Undergoing Curative Resection

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Mar 24
PMID 36959801
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Minimal residual disease (MRD) is considered an essential factor leading to relapse within 2 years (early relapse) after radical surgery, which is challenging to be detected by conventional imaging. Circulating tumor DNA (ctDNA) provides a novel approach for detecting MRD and predicting clinical outcomes. Here, we tried to construct a fixed panel for plasma-only ctDNA NGS to enable tumor-uninformed MRD detection in hepatocellular carcinoma (HCC).

Methods: Here, we performed the followings: (i) profiling genomic alteration spectrum of ctDNA from the Chinese HCC cohort consisting of 493 individuals by NGS; (ii) screening of MRD monitoring genes; and (iii) performance evaluation of MRD monitoring genes in predicting early relapse in the ZJZS2020 cohort comprising 20 HCC patients who underwent curative resection.

Results: A total of 493 plasma samples from the Chinese HCC cohort were detected using a 381/733-gene NGS panel to characterize the mutational spectrum of ctDNA. Most patients (94.1%, 464/493) had at least one mutation in ctDNA. The variants fell most frequently in (45.1%), (20.2%), (20.2%), (16.2%), and (13.4%). By customized filtering strategy, 13 MRD monitoring genes were identified, and any plasma sample with one or more MRD monitoring gene mutations was considered MRD-positive. In the ZJZS2020 cohort, MRD positivity presented a sensitivity of 75% (6/8) and a specificity of 100% (6/6) in identifying early postoperative relapse. The Kaplan-Meier analysis revealed a significantly short relapse-free survival (RFS; median RFS, 4.2 months . NR, P=0.002) in the MRD-positive patients versus those with MRD negativity. Cox regression analyses revealed MRD positivity as an independent predictor of poor RFS (HR 13.00, 95% CI 2.60-69.00, P=0.002).

Conclusions: We successfully developed a 13-gene panel for plasma-only MRD detection, which was effective and convenient for predicting the risk of early postoperative relapse in HCC.

Citing Articles

Non-Invasive Tumor-Naïve Minimal Residual Disease Detection of Liver Cancer by Incorporating Circulating Tumor DNA Features and Alpha-Fetoprotein: A Prospective Study.

Ren Q, Li S, Zhong G, Li Y, Huang D, Zhang L Cancer Med. 2024; 13(24):e70511.

PMID: 39704423 PMC: 11660314. DOI: 10.1002/cam4.70511.


Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.

Yang J, Lin N, Niu M, Yin B Aging (Albany NY). 2024; 16(14):11460-11474.

PMID: 39033781 PMC: 11315387. DOI: 10.18632/aging.205980.

References
1.
Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

2.
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts R . Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015; 7(302):302ra133. DOI: 10.1126/scitranslmed.aab0021. View

3.
Xiao G, Jin L, Liu C, Wang Y, Meng Y, Zhou Z . EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J Immunother Cancer. 2019; 7(1):300. PMC: 6854886. DOI: 10.1186/s40425-019-0784-9. View

4.
Tarazona N, Gimeno-Valiente F, Gambardella V, Zuniga S, Rentero-Garrido P, Huerta M . Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019; 30(11):1804-1812. DOI: 10.1093/annonc/mdz390. View

5.
Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K . Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg. 2012; 99(12):1711-7. DOI: 10.1002/bjs.8953. View